ArticlemBio2015
Subinhibitory antibiotic therapy alters recurrent urinary tract infection pathogenesis through modulation of bacterial virulence and host immunity.
Article in mBio, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 66 citations in OpenAlex.
- Continuous low-dose antibiotic prophylaxis for adults with repeated urinary tract infections (AnTIC): a randomised, open-label trial.The Lancet. Infectious diseases · 2018Trial
- UropathogenicInternational journal of molecular sciences · 2025Article
- Research Progress on Extracellular Matrix-Based Composite Materials in Antibacterial Field.Biomaterials research · 2025Review
- Article
- Previous Antibiotic Exposure Reshapes the Population Structure of Infecting Uropathogenic Escherichia coli Strains by Selecting for Antibiotic Resistance over Urovirulence.Microbiology spectrum · 2023Article
- The efficacy and safety of intravesical chondroitin sulphate solution in recurrent urinary tract infections.BMC urology · 2022Article
- Article
- Characterization of Escherichia coli isolated from urinary tract infection and association between virulence expression and antimicrobial susceptibility.BMC microbiology · 2022Article
- Curry Leaf Triggers Cell Death ofPathogens (Basel, Switzerland) · 2021Article
- Small-Molecule Compound SYG-180-2-2 to Effectively Prevent the Biofilm Formation of Methicillin-ResistantFrontiers in microbiology · 2021Article
- Recurrent Urinary Tract Infections: Unraveling the Complicated Environment of Uncomplicated rUTIs.Frontiers in cellular and infection microbiology · 2021Review
- Issues beyond resistance: inadequate antibiotic therapy and bacterial hypervirulence.FEMS microbes · 2020Review
- Review
- A Synthetic Peptide 2AbzDrug design, development and therapy · 2020Article
- Colonization of Mice With Amoxicillin-AssociatedFrontiers in microbiology · 2020Article
- Ciprofloxacin, amoxicillin, and aminoglycosides stimulate genetic and phenotypic changes in uropathogenic Escherichia coli strains.Virulence · 2019Article
- Sublethal antibiotics collapse gut bacterial populations by enhancing aggregation and expulsion.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Update on Associated Risk Factors, Diagnosis, and Management of Recurrent Urinary Tract Infections in Children.Journal of the Pediatric Infectious Diseases Society · 2019Review
- Subinhibitory concentrations of tedizolid potently inhibit extracellular toxin production by methicillin-sensitive and methicillin-resistant Staphylococcus aureus.Journal of medical microbiology · 2019Article
- The SOS Response Mediates Sustained Colonization of the Mammalian Gut.Infection and immunity · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
unlabelledThe capacity of subinhibitory levels of antibiotics to modulate bacterial virulence in vitro has recently been brought to light, raising concerns over the appropriateness of low-dose therapies, including antibiotic prophylaxis for recurrent urinary tract infection management. However, the mechanisms involved and their relevance in influencing pathogenesis have not been investigated. We characterized the ability of antibiotics to modulate virulence in the uropathogens Staphylococcus saprophyticus and Escherichia coli. Several antibiotics were able to induce the expression of adhesins critical to urothelial colonization, resulting in increased biofilm formation, colonization of murine bladders and kidneys, and promotion of intracellular niche formation. Mice receiving subinhibitory ciprofloxacin treatment were also more susceptible to severe infections and frequent recurrences. A ciprofloxacin prophylaxis model revealed this strategy to be ineffective in reducing recurrences and worsened infection by creating larger intracellular reservoirs at higher frequencies. Our study indicates that certain agents used for antibiotic prophylaxis have the potential to complicate infections. IMPORTANCE: Antibiotics are the mainstay treatment for bacterial infections; however, evidence is emerging that argues these agents may have off-target effects if sublethal concentrations are present. Most studies have focused on changes occurring in vitro, leaving questions regarding the clinical relevance in vivo. We utilized a murine urinary tract infection model to explore the potential impact of low-dose antibiotics on pathogenesis. Using this model, we showed that subinhibitory antibiotics prime uropathogens for adherence and invasion of murine urothelial tissues. These changes in initial colonization promoted the establishment of chronic infection. Furthermore, treatment of chronically infected mice with subtherapeutic ciprofloxacin served to exacerbate infection. A part of these changes was thought to be due to suppression of mucosal immunity, as demonstrated through reductions in cytokine secretion and migration of leukocytes into the urinary tract. This work identifies novel risk factors associated with antibiotic therapy when dosing strategies fall below subtherapeutic levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.